Performance of BMRN Biomarin Pharmaceutical | -13% in 12m
Compare BMRN with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Biomarin Pharmaceutical with its related Sector/Index XBI
Performance Duell BMRN vs XBI
| TimeFrame | BMRN | XBI |
|---|---|---|
| 1 Day | -1.53% | 1.54% |
| 1 Week | -8.71% | 0.80% |
| 1 Month | -7.78% | -9.93% |
| 3 Months | -11.0% | -5.38% |
| 6 Months | -1.29% | 26.18% |
| 12 Months | -13.0% | 5.24% |
| YTD | -17.5% | -7.47% |
| Rel. Perf. 1m | 0.75 | |
| Rel. Perf. 3m | -1.69 | |
| Rel. Perf. 6m | -2.16 | |
| Rel. Perf. 12m | -1.59 |
Is Biomarin Pharmaceutical a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Biomarin Pharmaceutical is currently (April 2024)
neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 26.55 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BMRN as of April 2024 is 72.85. This means that BMRN is currently overvalued and has a potential downside of -9.96% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BMRN as of April 2024 is 72.85. This means that BMRN is currently overvalued and has a potential downside of -9.96% (Sold with Premium).
Is BMRN a buy, sell or hold?
- Strong Buy: 14
- Buy: 7
- Hold: 9
- Sell: 0
- Strong Sell: 0
Values above 0%: BMRN is performing better - Values below 0%: BMRN is underperforming
Compare BMRN with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -11.36% | -5.75% | -25.37% | -40.52% |
| US NASDAQ 100 | QQQ | -12.65% | -5.00% | -27.19% | -52.12% |
| US Dow Jones Industrial 30 | DIA | -9.37% | -5.15% | -19.00% | -30.05% |
| German DAX 40 | DBXD | -11.05% | -6.43% | -24.33% | -27.27% |
| UK FTSE 100 | ISFU | -12.22% | -9.33% | -17.02% | -20.51% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -9.62% | -9.10% | -3.77% | -1.21% |
| Hongkong Hang Seng | HSI | -17.42% | -9.76% | 0.42% | 5.47% |
| Japan Nikkei 225 | EXX7 | -8.64% | 0.23% | -18.37% | -30.79% |
| India NIFTY 50 | INDA | -10.64% | -10.85% | -23.73% | -43.20% |
| Brasil Bovespa | EWZ | -11.31% | -5.55% | -8.40% | -34.96% |
BMRN Biomarin Pharmaceutical vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -9.52% | -6.23% | -28.46% | -57.05% |
| Consumer Discretionary | XLY | -12.33% | -4.25% | -20.59% | -36.38% |
| Consumer Staples | XLP | -10.25% | -7.94% | -14.96% | -15.13% |
| Energy | XLE | -9.52% | -11.24% | -13.67% | -31.58% |
| Financial | XLF | -9.80% | -6.38% | -29.84% | -41.79% |
| Health Care | XLV | -9.44% | -3.79% | -13.93% | -21.01% |
| Industrial | XLI | -10.53% | -6.74% | -28.44% | -41.42% |
| Materials | XLB | -9.34% | -5.80% | -21.95% | -29.31% |
| Real Estate | XLRE | -10.33% | -2.95% | -14.15% | -16.62% |
| Technology | XLK | -12.50% | -4.01% | -26.52% | -50.88% |
| Utilities | XLU | -9.87% | -12.13% | -13.83% | -13.30% |
| Aerospace & Defense | XAR | -11.64% | -6.03% | -21.09% | -34.99% |
| Biotech | XBI | -9.51% | 2.15% | -27.47% | -18.24% |
| Homebuilder | XHB | -12.26% | -2.65% | -50.06% | -67.74% |
| Retail | XRT | -11.59% | -3.07% | -27.07% | -35.37% |
Does Biomarin Pharmaceutical outperform its market, is BMRN a Sector Leader?
No, over the last 12 months Biomarin Pharmaceutical (BMRN) made -13.00%, while its related Sector, the SPDR S&P Biotech (XBI) made 5.24%.
Over the last 3 months BMRN made -10.96%, while XBI made -5.38%.
No, over the last 12 months Biomarin Pharmaceutical (BMRN) made -13.00%, while its related Sector, the SPDR S&P Biotech (XBI) made 5.24%.
Over the last 3 months BMRN made -10.96%, while XBI made -5.38%.
| Period | BMRN | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -7.78% | -9.93% | -2.03% |
| 3 Months | -10.96% | -5.38% | 4.60% |
| 12 Months | -13.00% | 5.24% | 27.52% |